News & Views
Hybrigenics Benefits from Tax Measure in Support of Innovation
Jun 11 2009
Hybrigenics, a bio-pharmaceutical company with a focus on research and development of new cancer treatments and specialist in protein interactions, has received notification from the French Finance Administration of reimbursement of EUR 507,000 for cumulated 2005-2007 Research Tax Credit (RTC) and EUR 865,000 for 2008 RTC. The effective enactment of this decision will result in EUR 1.37 million cash payment to the company in the coming weeks.
"We filed our application in February; the administration answered positively before end of March," said Remi Delansorne, Hybrigenics’ CEO, "This demonstrates a clear and efficient impetus in favour of innovative companies like Hybrigenics to continue to invest in R&D."
Its development of inecalcitol in hormonerefractory prostate cancer progressed nicely in 2008 with the ongoing clinical tolerance Phase II trial. This resulted in the approval by the French Drug Regulatory Agency to speed up dose escalation ahead of schedule: 1,000 micrograms/day is the dose level currently being tested. In addition, the American Food and Drug Administration recently validated the development plan of inecalcitol for US patients. The RTC funds will help to move quickly to the next steps of clinical development.
Digital Edition
ILM 49.5 July
July 2024
Chromatography Articles - Understanding PFAS: Analysis and Implications Mass Spectrometry & Spectroscopy Articles - MS detection of Alzheimer’s blood-based biomarkers LIMS - Essent...
View all digital editions
Events
Jul 28 2024 San Diego, CA USA
Jul 30 2024 Jakarta, Indonesia
Jul 31 2024 Chengdu, China
ACS National Meeting - Fall 2024
Aug 18 2024 Denver, CO, USA
Aug 25 2024 Copenhagen, Denmark